NEW YORK (GenomeWeb News) –GeneGo said today that Proteostasis Therapeutics has licensed its MetaCore curated data mining and analysis platform.
Proteostasis Therapeutics is developing small molecule therapeutics based on studies of the human proteostasis network, the balance of proteins that can protect the body from diseases, GeneGo said. Deficiencies in that network can lead to a range of diseases, such as emphysema, type II diabetes, Alzheimer's disease, and Huntington's disease, said GeneGo.
St. Joseph, Mich.-based GeneGo is developing pathway reconstruction maps for a number of diseases, including neurodegenerative disorders.
Proteostasis Therapeutics will use MetaCore's curated database of protein interactions in its protein characterization-focused efforts to discover small molecules that could be used to treat diseases.
Financial terms of the agreement were not released.